Suppliers and packagers for generic pharmaceutical drug: LIRAGLUTIDE

LIRAGLUTIDE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Hikma	LIRAGLUTIDE	liraglutide	SOLUTION;SUBCUTANEOUS	215503	ANDA	Hikma Pharmaceuticals USA Inc.	0143-9144-02	2 SYRINGE, PLASTIC in 1 CARTON (0143-9144-02) / 3 mL in 1 SYRINGE, PLASTIC	2024-12-24
Hikma	LIRAGLUTIDE	liraglutide	SOLUTION;SUBCUTANEOUS	215503	ANDA	Hikma Pharmaceuticals USA Inc.	0143-9144-03	3 SYRINGE, PLASTIC in 1 CARTON (0143-9144-03) / 3 mL in 1 SYRINGE, PLASTIC	2024-12-24
Hikma	LIRAGLUTIDE	liraglutide	SOLUTION;SUBCUTANEOUS	215503	ANDA	Hybio Pharmaceutical Co., Ltd. (Pingshan Factory)	14403-3400-1	3 mL in 1 SYRINGE, PLASTIC (14403-3400-1)	2024-06-21

Liraglutide Supplier Landscape Analysis

Last updated: February 19, 2026

Overview

This report details the key suppliers and associated patent landscapes for liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist used in the treatment of type 2 diabetes and obesity. The analysis identifies major active pharmaceutical ingredient (API) manufacturers, contract development and manufacturing organizations (CDMOs), and highlights relevant patent expirations and ongoing intellectual property challenges. Understanding this supply chain is critical for manufacturers seeking to enter the generic liraglutide market and for investors assessing market opportunities.

Key Liraglutide API Manufacturers

The production of liraglutide API is complex, involving peptide synthesis and requires specialized manufacturing capabilities. The market is dominated by a limited number of established players, alongside emerging suppliers.

• Novo Nordisk: As the innovator and original patent holder, Novo Nordisk is a primary manufacturer of liraglutide API for its branded products Victoza and Saxenda. Their internal manufacturing capacity remains a significant factor in the market.
• Polypeptide Group: A leading global manufacturer of peptide-based APIs, Polypeptide Group is known to supply liraglutide API to various pharmaceutical companies, including generic manufacturers. They possess extensive experience in complex peptide synthesis.
• Bachem: Another prominent peptide API manufacturer, Bachem offers custom synthesis services and is a potential supplier for liraglutide. Their expertise in solid-phase and solution-phase peptide synthesis is relevant.
• AmbioPharm: This company specializes in peptide API manufacturing and has been identified as a supplier for liraglutide, catering to the needs of generic drug developers.
• Hyglos: While more focused on biologics and vaccines, Hyglos's parent company, Bioserv, has expertise in protein and peptide manufacturing, potentially positioning them as a future supplier or partner.
• Peptide Sciences: Offers custom peptide synthesis and may be involved in supplying liraglutide API to specific clients.

Contract Development and Manufacturing Organizations (CDMOs) in Liraglutide Production

CDMOs play a crucial role in the liraglutide supply chain, particularly for companies without in-house manufacturing capabilities. These organizations provide services ranging from process development and scale-up to commercial manufacturing of both API and finished drug product.

• Lonza: A major global CDMO with extensive experience in peptide manufacturing and biopharmaceutical production. Lonza has the capacity and regulatory expertise to support liraglutide production.
• Catalent: Offers a broad range of development and manufacturing services, including complex API synthesis and sterile fill-finish for injectable drugs like liraglutide.
• WuXi AppTec: A leading global pharmaceutical, biopharmaceutical, and medical device outsourcing company. WuXi AppTec provides end-to-end services, including API development and manufacturing, for peptide therapeutics.
• Ajinomoto Bio-Pharma Services: Known for its expertise in biopharmaceutical manufacturing, including large-scale cell culture and protein purification, which can be relevant for complex peptide APIs or associated biologics.
• CordenPharma: Specializes in the development and manufacturing of highly potent APIs, peptides, and lipids. Their peptide manufacturing capabilities are directly applicable to liraglutide.

Liraglutide Patent Landscape and Expirations

The intellectual property surrounding liraglutide significantly impacts market entry for generic manufacturers. Novo Nordisk holds foundational patents, but several have expired or are nearing expiration, creating opportunities.

Key Patent Expirations

Patent Number	Title/Description	Filing Date	Expiration Date	Status	Notes
US 7,432,311	GLP-1 Receptor Agonists	2001-10-03	2024-01-23	Expired	Core patent for liraglutide molecule.
US 7,662,806	GLP-1 Receptor Agonists	2002-05-15	2024-01-14	Expired	Related to GLP-1 receptor agonist compositions.
EP 1 354 950	GLP-1 Receptor Agonists	2001-10-03	2023-03-10	Expired	European counterpart to US 7,432,311.
US 7,129,351	Methods of Treating Diabetes	2001-06-27	2022-07-03	Expired	Method of use patent for type 2 diabetes treatment.
US 8,815,838	Compositions for Administering GLP-1 Receptor Agonists	2008-07-30	2029-01-30	Active	Formulation and administration patent.
US 9,173,149	GLP-1 Receptor Agonists	2009-12-18	2029-12-18	Active	Further patent on GLP-1 receptor agonists.
US 9,474,799	Pharmaceutical Compositions	2010-09-07	2030-09-07	Active	Formulation and method of use.
US 9,745,315	GLP-1 Receptor Agonists	2014-04-18	2032-04-18	Active	Process and compound patent.
US 10,525,149	Pharmaceutical Compositions and Methods of Use Thereof	2017-01-17	2035-01-17	Active	Formulation and method of use.
US 10,954,350	GLP-1 Receptor Agonists for Weight Management	2018-06-14	2038-06-14	Active	Specifically relates to weight management use.

Source: U.S. Patent and Trademark Office (USPTO), European Patent Office (EPO), and publicly available patent databases. Dates reflect national stage entries or priority dates, with expiration calculated as 20 years from filing plus potential extensions.

The expiration of foundational composition of matter patents, such as US 7,432,311, opens the door for generic liraglutide development. However, active patents related to specific formulations, manufacturing processes, and methods of use can present ongoing challenges and require careful navigation by generic manufacturers.

Ongoing Litigation and Challenges

Novo Nordisk has actively defended its intellectual property through patent litigation against potential generic competitors. These challenges often focus on alleged infringement of formulation patents, manufacturing process patents, or method of use patents, particularly for the weight management indication.

• Infringement Lawsuits: Several generic companies have faced or are currently involved in patent infringement lawsuits filed by Novo Nordisk. These lawsuits aim to prevent the launch of generic versions of liraglutide until the expiration of all relevant patents.
• Paragraph IV Certifications: Generic manufacturers often file Abbreviated New Drug Applications (ANDAs) with the U.S. Food and Drug Administration (FDA) and include Paragraph IV certifications, challenging the validity or non-infringement of existing patents. This process frequently leads to litigation.
• Patent Linkage: The FDA's Orange Book lists patents covering approved drugs. Generic applicants must address these patents, either by demonstrating non-infringement, invalidity, or waiting for patent expiration.
• Manufacturing Process Patents: Patents claiming specific synthesis routes, purification methods, or polymorphic forms of liraglutide can be critical barriers. Generic manufacturers must develop non-infringing processes.

Liraglutide Market Dynamics and Outlook

The liraglutide market is characterized by the significant growth of its use in both type 2 diabetes and obesity management. The increasing prevalence of these conditions globally drives demand.

• Market Size: The global liraglutide market was valued at approximately USD 4.9 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of over 7% from 2023 to 2030. [1]
• Indications: Liraglutide is approved for:
  • Type 2 Diabetes (Victoza)
  • Chronic Weight Management (Saxenda)
• Competition: While Novo Nordisk holds a dominant position, the market is expected to see increased competition with the entry of generic versions of liraglutide. Competitors include semaglutide (Ozempic, Wegovy), dulaglutide (Trulicity), and tirzepatide (Mounjaro).
• Generic Entry: The patent expiries of key liraglutide patents have created a pathway for generic manufacturers. Companies that successfully navigate the patent landscape and regulatory hurdles are positioned to capture market share.
• Manufacturing Challenges: The complex peptide nature of liraglutide API presents significant manufacturing challenges, including:
  • Purity: Achieving high purity levels required for pharmaceutical applications.
  • Scale-up: Transitioning from laboratory-scale synthesis to commercial-scale production.
  • Cost of Goods: Managing the expenses associated with raw materials and complex synthesis processes.
  • Regulatory Compliance: Adhering to stringent Good Manufacturing Practices (GMP) standards.

Key Takeaways

• Supply Chain Concentration: The liraglutide API and CDMO market is characterized by a core group of specialized manufacturers and service providers with expertise in peptide synthesis.
• Patent Expiration Impact: The expiration of key composition of matter patents has created opportunities for generic liraglutide development.
• Ongoing IP Hurdles: Active patents related to formulations, manufacturing processes, and methods of use present ongoing challenges for generic entrants, often leading to patent litigation.
• Market Growth Drivers: The rising global incidence of type 2 diabetes and obesity fuels demand for liraglutide, creating a substantial market for both branded and generic products.
• Manufacturing Expertise is Paramount: Successful entry into the liraglutide market requires robust peptide manufacturing capabilities, efficient process development, and a thorough understanding of the complex patent landscape.

Frequently Asked Questions

1. Which patents for liraglutide have already expired, and what is their significance for generic manufacturers? Foundational patents covering the liraglutide molecule itself, such as U.S. Patent No. 7,432,311 and EP 1 354 950, have expired. This allows generic companies to develop and market liraglutide without infringing these core composition of matter claims, provided they do not infringe other active patents.

2. What are the primary challenges generic manufacturers face when developing liraglutide? Key challenges include developing non-infringing manufacturing processes, navigating existing formulation and method-of-use patents, achieving the required API purity and stability, and scaling production efficiently to meet market demand while managing costs.

3. Who are the major API suppliers for liraglutide, and do they supply to both innovator and generic companies? Major API suppliers include Polypeptide Group, Bachem, and AmbioPharm. These companies often supply API to generic manufacturers. Novo Nordisk, the innovator, primarily manufactures its own API internally but may also engage external suppliers for specific needs or under different agreements.

4. What is the role of CDMOs in the liraglutide supply chain, and which ones are most relevant? CDMOs provide crucial services like process development, API manufacturing, and finished drug product formulation and filling. Key CDMOs with relevant expertise in peptide synthesis and sterile injectables include Lonza, Catalent, WuXi AppTec, and CordenPharma.

5. Beyond type 2 diabetes, what other indications for liraglutide have active patents, and how do these affect market entry? The patent for the weight management indication (e.g., U.S. Patent No. 10,954,350) remains active and extends further into the future. This specific patent creates a longer barrier to entry for generic versions targeting obesity, requiring generic companies to either wait for its expiration or successfully challenge its validity or non-infringement.

Citations

[1] Grand View Research. (2023). Liraglutide Market Size, Share & Trends Analysis Report By Application (Type 2 Diabetes, Obesity), By Region, And Segment Forecasts, 2023 - 2030. Retrieved from https://www.grandviewresearch.com/industry-analysis/liraglutide-market